Suzana Matkovic
Belgrade, SE, Serbia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 16, 2026
Analyses of peripheral blood NK cells in response to anti-PD-1 therapy in metastatic melanoma patients.
Journal: Clinical immunology (Orlando, Fla.)
Published: February 04, 2025
Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients.
Journal: Translational oncology
Published: August 16, 2023
Longitudinal evaluation of health-related quality of life after removal of high-risk melanoma in a setting where adjuvant therapy is not available.
Journal: Archives of dermatological research
Published: January 26, 2023
Circulating IL-6 is associated with disease progression in BRAFwt metastatic melanoma patients receiving anti-PD-1 therapy.
Journal: Journal of clinical pathology
Published: October 07, 2022
Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting.
Journal: Frontiers in oncology
Published: March 08, 2022
Favorable in vitro effects of combined IL-12 and IL-18 treatment on NK cell cytotoxicity and CD25 receptor expression in metastatic melanoma patients.
Journal: Journal of translational medicine
Published: December 04, 2014
Significance of tumor burden, vascular endothelial growth factor, lactate dehydrogenase and beta-2 microglobulin serum levels in advanced diffuse large B cell lymphoma.
Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology
Published: October 04, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026